Received May 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
potential underdose/ liquid ran down his arm after the injection; blood and liquid at injection site/ He states that the person administering the injection pinched the skin and then blood; He states that he suspects the person administering the Twinrix administered it subcutaneously.; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site hemorrhage in a 78-year-old male patient who received HAB (Twinrix) for prophylaxis. On 15-MAY-2026, the patient received the 1st dose of Twinrix. On 15-MAY-2026, an unknown time after receiving Twinrix, the patient experienced injection site hemorrhage (Verbatim: blood and liquid at injection site/ He states that the person administering the injection pinched the skin and then blood) and intramuscular formulation administered by other route (Verbatim: He states that he suspects the person administering the Twinrix administered it subcutaneously.). On an unknown date, the patient experienced accidental underdose (Verbatim: potential underdose/ liquid ran down his arm after the injection). The outcome of the injection site hemorrhage was unknown and the outcome of the intramuscular formulation administered by other route and accidental underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:18-MAY-2026 The batch number was not provided upon follow-up with the reporter.